2. Academic Validation
  3. PCSK9 promotes progression of anaplastic thyroid cancer through E-cadherin endocytosis

PCSK9 promotes progression of anaplastic thyroid cancer through E-cadherin endocytosis

  • Cell Death Dis. 2025 May 6;16(1):362. doi: 10.1038/s41419-025-07690-1.
Yu Zhang # 1 2,  Wei Su # 2 3,  Xiaoyu Ji # 4,  Zhou Yang 1 2,  Qing Guan 1 2,  Yuanxin Pang 5,  Linkun Zhong 6,  Yu Wang 7 8,  Jun Xiang 9 10
Affiliations

Affiliations

  • 1 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • 3 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • 4 Department of Oncology, Huashan Hospital Fudan University, Shanghai, China.
  • 5 Department of Endocrinology, Suzhou Ninth People's Hospital Affiliated to Soochow University, Suzhou, China. laxi60383@163.com.
  • 6 Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, Guangdong Province, China. zhonglksysu@163.com.
  • 7 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. wangyu@shca.org.cn.
  • 8 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. wangyu@shca.org.cn.
  • 9 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. xiangjun@shca.org.cn.
  • 10 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. xiangjun@shca.org.cn.
  • # Contributed equally.
PMID: 40328788 DOI: 10.1038/s41419-025-07690-1
Abstract

Although anaplastic thyroid Cancer (ATC) constitutes only 1-2% of all thyroid malignancies, it is associated with an exceptionally high mortality rate, accounting for 14-39% of thyroid cancer-related deaths. In this study, we identified the critical role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in ATC progression. Proteomic analysis revealed E-cadherin as a key mediator of PCSK9-driven malignancy in ATC. Mechanistically, PCSK9 promotes the degradation of E-cadherin through the lysosomal pathway. Furthermore, the loss of the p53 function, particularly the R248Q mutation, de-repressed PCSK9 expression at the transcriptional level. Notably, the PCSK9 Inhibitor PF-846 considerably suppressed ATC proliferation and metastasis in both in vitro and in vivo models. In conclusion, PCSK9 enhances ATC malignancy by regulating E-cadherin degradation via the lysosomal pathway, underscoring its potential as a promising therapeutic target.

Figures
Products